Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets
Researchers identified new molecular subtypes in acute myeloid leukemia and pinpointed a drug-resistance driver, opening pathways for more targeted treatment approaches.
The CPTAC consortium applied 13 omics modalities to 173 treatment-naive AML patients, defining new molecular subtype architecture with extensive metabolomic/lipidomic reprogramming. A machine-learning multiomic approach nominated and validated MTA1 as a panobinostat resistance driver, offering actionable precision therapy targets across AML subtypes.
What the study was
- Study design
- Multiomics profiling study (13 modalities)
- Population
- Treatment-naive AML patients
- Sample size
- 173
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Nature Cancer
Why it surfaced
Nature Cancer CPTAC flagship; 13-modality AML atlas at n=173 defines new subtype architecture and validated resistance target (MTA1); highest-impact hematology-precision oncology article this run.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.